Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Novartis completed its acquisition strategy by securing the final 23% of Alcon shares using a combination of cash and stock valued at $12.9 billion,…
Novartis and Alcon completed their merger, with Novartis acquiring all remaining Alcon shares in a deal valuing the total acquisition at approximately…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis completed its full acquisition of Alcon for approximately $51.6 billion across multiple stages, having first acquired a 25% stake from Nestle in 2008, then the remaining 52% Nestle stake in 2010, and finally merging in the 23% minority shares in 2011, creating the global leader in eye care.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Alcon Inc. (this deal) | 2010 | $51.6B | 33 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2010 deals · Novartis AG deals · Infectious Disease deals